Melanoma: all 3,073 studies
Page 22 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaWithdrawnNCT02447939Phase 1
- Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human MelanomaTerminatedNCT02442466Early Phase 1
- Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive MalignanciesCompletedNCT02441465Phase 1
- Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in SpainCompletedNCT02439411
- Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune ResponseTerminatedNCT02439008Not applicable
- Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
- Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1
- Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)CompletedNCT02434107Not applicable
- Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
- Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaWithdrawnNCT02427893Phase 3
- FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA)CompletedNCT02425475
- Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II StudyCompletedNCT02424916Phase 1/2
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1
- Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous MelanomaNo longer availableNCT02416232
- Vemurafenib Plus Cobimetinib in Metastatic MelanomaTerminatedNCT02414750Phase 2
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
- Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced MelanomaTerminatedNCT02410863Phase 2
- Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced MelanomaCompletedNCT02410733Phase 1
- Trial of SBRT With Concurrent Ipilimumab in Metastatic MelanomaCompletedNCT02406183Phase 1
- Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in TaiwanCompletedNCT02402699
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
- Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy TechniquesCompletedNCT02393001
- Radiotherapy & Combi in Metastatic MelanomaCompletedNCT02392871Phase 1/2
- A Study of rSIFN-co in Subjects With Advanced Solid TumorsCompletedNCT02387307Phase 1
- Training Primary Care Physicians to Perform Melanoma Opportunistic SurveillanceCompletedNCT02385253Not applicable
- MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous MelanomaActive, not recruitingNCT02385214Not applicable
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibTerminatedNCT02382549Early Phase 1
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
- TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyStatus unknownNCT02379000Phase 4
- 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient OutcomesCompletedNCT02376920
- Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesActive, not recruitingNCT02374242Phase 2
- Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser TherapyCompletedNCT02372708
- Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWithdrawnNCT02357732Phase 1
- Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient OutcomesTerminatedNCT02355587
- 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay ResultsTerminatedNCT02355574
- Quality of Life and Surgical Late Effects of Melanoma TreatmentCompletedNCT02352623
- Inducing Systemic Immunity and Regressions in Metastatic MelanomaCompletedNCT02350972Phase 1
- Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor InfiltrationTerminatedNCT02339987
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
- Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bCompletedNCT02339324Phase 1
- Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence TomographyStatus unknownNCT02335476
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma RecurrenceCompletedNCT02334735Phase 2
- Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under ChemotherapyCompletedNCT02332642
- Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV MelanomaTerminatedNCT02327390Phase 1
- MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by SurgeryCompletedNCT02320305Early Phase 1
- Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung CancerCompletedNCT02318771Phase 1
- Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and MelanomaCompletedNCT02316795Early Phase 1
- Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of ExosomesCompletedNCT02310451Not applicable
- Pancreatic Cancer Screening of High-Risk Individuals in ArkansasWithdrawnNCT02309632Not applicable
- Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic MelanomaCompletedNCT02308553Phase 1/2
- PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyActive, not recruitingNCT02307630Not applicable
- Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedNCT02307149Phase 1
- Mohs and Immunofluorescence for Malignant Melanoma In SituWithdrawnNCT02306512Not applicable
- Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
- Study of Trametinib and Nab-paclitaxel in Patients With MelanomaWithdrawnNCT02300935Phase 1
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
- Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c MelanomaNo longer availableNCT02297529
- Dabrafenib and Trametinib for BRAF-inhibitor Pretreated PatientsCompletedNCT02296996Phase 2
- Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma PatientsCompletedNCT02285413Phase 2
- A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer CareActive, not recruitingNCT02279004
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
- Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaCompletedNCT02275416Phase 1/2
- Trial of AEB071 in Combination With BYL719 in Patients With MelanomaCompletedNCT02273219Phase 1
- A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaCompletedNCT02272855Phase 2
- Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsWithdrawnNCT02263898Phase 2
- Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT02257424Phase 1/2
- Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant MelanomaCompletedNCT02251314
- Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationActive, not recruitingNCT02231775Phase 2
- YERVOY® Risk Minimization Tool Effectiveness Evaluation SurveyCompletedNCT02224768
- A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained TherapyCompletedNCT02223884Phase 2
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Patient Preference for Biopsy NotificationCompletedNCT02213471
- Adoptive Therapy Using Antigen-Specific CD4 T-CellsWithdrawnNCT02210104Phase 1
- Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant MelanomaCompletedNCT02203864Phase 1
- Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaStatus unknownNCT02202200Phase 1/2
- Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
- Moletest Clinical Study in ScotlandCompletedNCT02196246
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingNCT02196181Phase 2
- Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical ImagingCompletedNCT02193581
- Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated MelanomaTerminatedNCT02190838Phase 2
- Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaNo longer availableNCT02186249
- A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant MelanomaCompletedNCT02177110
- The Oncopanel Pilot (TOP) StudyCompletedNCT02171286
- Evaluation of Groin Lymphadenectomy Extent For Metastatic MelanomaCompletedNCT02166788Phase 3
- APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT02166255Phase 1
- Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c MelanomaNo longer availableNCT02147951
- Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain MetastasesWithdrawnNCT02145910Phase 1
- An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic MelanomaCompletedNCT02143999
- Study of Dabrafenib, Trametinib and Metformin for Melanoma PatientsWithdrawnNCT02143050Phase 1/2
- Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant MelanomaStatus unknownNCT02142335Phase 2
- Fluorescence Surgery for Sentinel Node Identification in MelanomaStatus unknownNCT02142244Not applicable
- Expanded Access Program With Nivolumab to Treat MelanomaNo longer availableNCT02142218
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT02141542Phase 1
- A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type MelanomaCompletedNCT02138292Phase 1
- Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After ChemotherapyCompletedNCT02133222Not applicable
- Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenCompletedNCT02129049Not applicable
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1CompletedNCT02122861Phase 1
- Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By SurgeryCompletedNCT02120222Phase 1
- Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02117362Phase 1
- Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity MelanomaCompletedNCT02115243Phase 1